CZ298749B6
(cs)
|
1996-10-18 |
2008-01-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
CA2429359A1
(en)
|
2000-11-20 |
2002-08-08 |
Bristol-Myers Squibb Company |
Hepatitis c tripeptide inhibitors
|
US6867185B2
(en)
*
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
AU2003301959A1
(en)
|
2002-05-20 |
2004-06-03 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
ATE503764T1
(de)
|
2002-05-20 |
2011-04-15 |
Bristol Myers Squibb Co |
Inhibitoren des hepatitis-c-virus
|
ES2350201T3
(es)
|
2002-05-20 |
2011-01-20 |
Bristol-Myers Squibb Company |
Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c.
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US20050159345A1
(en)
*
|
2002-10-29 |
2005-07-21 |
Boehringer Ingelheim International Gmbh |
Composition for the treatment of infection by Flaviviridae viruses
|
US7176208B2
(en)
*
|
2003-04-18 |
2007-02-13 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
|
PL1654261T3
(pl)
|
2003-05-21 |
2008-04-30 |
Boehringer Ingelheim Int |
Związki hamujące aktywność wirusa zapalenia wątroby typu C
|
US7521420B2
(en)
|
2003-06-18 |
2009-04-21 |
Tranzyme Pharma, Inc. |
Macrocyclic antagonists of the motilin receptor
|
AR045596A1
(es)
|
2003-09-05 |
2005-11-02 |
Vertex Pharma |
Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
|
PE20050431A1
(es)
*
|
2003-09-22 |
2005-07-19 |
Boehringer Ingelheim Int |
Peptidos macrociclicos activos contra el virus de la hepatitis c
|
US7491794B2
(en)
*
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
TWI375679B
(en)
*
|
2003-10-14 |
2012-11-01 |
Hoffmann La Roche |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2005053735A1
(en)
|
2003-11-20 |
2005-06-16 |
Boehringer Ingelheim International Gmbh |
Method of removing transition metals, especially from metathesis reaction products
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
DE602004019973D1
(de)
*
|
2003-12-08 |
2009-04-23 |
Boehringer Ingelheim Int |
Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten
|
EP1730167B1
(de)
*
|
2004-01-21 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
|
BRPI0506945A
(pt)
|
2004-01-30 |
2007-06-12 |
Medivir Ab |
inibidores de serina protease ns-3 de hcv
|
TWI368507B
(en)
|
2004-02-20 |
2012-07-21 |
Boehringer Ingelheim Int |
Viral polymerase inhibitors
|
AP2006003763A0
(en)
*
|
2004-03-30 |
2006-10-31 |
Intermune Inc |
Macrocyclic compounds as inhibitors of viral replication
|
WO2005118620A2
(en)
|
2004-05-27 |
2005-12-15 |
New York University |
Methods for preparing internally constraied peptides and peptidomimetics
|
EP2316839B1
(de)
*
|
2004-07-16 |
2014-03-12 |
Gilead Sciences, Inc. |
Antivirale heterocyclische verbindungen mit phosphonatgruppen
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
CA2573346C
(en)
|
2004-07-20 |
2011-09-20 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
EP1794178A1
(de)
*
|
2004-09-17 |
2007-06-13 |
Boehringer Ingelheim International Gmbh |
Verfahren zur herstellung makrocyclischer inhibitoren der hcv-protease
|
US7189844B2
(en)
*
|
2004-09-17 |
2007-03-13 |
Boehringer Ingelheim International Gmbh |
Ring-closing metathesis process in supercritical fluid
|
US20080267915A1
(en)
*
|
2004-10-01 |
2008-10-30 |
Vertex Pharmaceuticals |
Hcv Ns3-Ns4a Protease Inhibition
|
EP1805187A1
(de)
*
|
2004-10-21 |
2007-07-11 |
Pfizer, Inc. |
Inhibitoren der hepatits-c-virus-protease und zusammensetzungen und behandlungen damit
|
MY141025A
(en)
|
2004-10-29 |
2010-02-25 |
Vertex Pharma |
Dose forms
|
DE102005002336A1
(de)
*
|
2005-01-17 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2006242475B2
(en)
*
|
2005-05-02 |
2011-07-07 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7470664B2
(en)
*
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
NZ565059A
(en)
*
|
2005-07-25 |
2011-08-26 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitus C virus replication
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
US8278322B2
(en)
*
|
2005-08-01 |
2012-10-02 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
US8076365B2
(en)
|
2005-08-12 |
2011-12-13 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
JP2009511595A
(ja)
|
2005-10-11 |
2009-03-19 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルスの複製を阻害する化合物および方法
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
JP5436864B2
(ja)
|
2006-02-27 |
2014-03-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vx−950を含む共結晶体およびそれを含む医薬組成物
|
MX2008011868A
(es)
|
2006-03-16 |
2008-12-15 |
Vertex Pharma |
Inhibidores deuterados de la proteasa de la hepatitis c.
|
GB0609492D0
(en)
*
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
KR20090024834A
(ko)
*
|
2006-07-05 |
2009-03-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 억제제
|
EP2049474B1
(de)
|
2006-07-11 |
2015-11-04 |
Bristol-Myers Squibb Company |
Hemmer des hepatitis-c-virus
|
US7718612B2
(en)
*
|
2007-08-02 |
2010-05-18 |
Enanta Pharmaceuticals, Inc. |
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
|
MX2009000882A
(es)
|
2006-08-17 |
2009-02-04 |
Boehringer Ingelheim Int |
Inhibidores de la polimerasa virica.
|
CA2667266C
(en)
*
|
2006-10-24 |
2015-11-24 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
JP2010507656A
(ja)
|
2006-10-24 |
2010-03-11 |
メルク エンド カムパニー インコーポレーテッド |
Hcvns3プロテアーゼ阻害剤
|
EP2079479B1
(de)
*
|
2006-10-24 |
2014-11-26 |
Merck Sharp & Dohme Corp. |
Inhibitoren der hcv-ns3-protease
|
MX2009004556A
(es)
|
2006-10-27 |
2009-07-10 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del hcv.
|
ES2444575T3
(es)
*
|
2006-10-27 |
2014-02-25 |
Merck Sharp & Dohme Corp. |
Inhibidores de la proteasa NS3 del VHC
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008075103A1
(en)
|
2006-12-20 |
2008-06-26 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Antiviral indoles
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CN101627020B
(zh)
*
|
2007-02-08 |
2015-06-17 |
泰博特克药品有限公司 |
抑制hcv的大环苯基氨基甲酸酯
|
CN101903392A
(zh)
|
2007-02-27 |
2010-12-01 |
弗特克斯药品有限公司 |
丝氨酸蛋白酶的抑制剂
|
EA200970806A1
(ru)
|
2007-02-27 |
2010-08-30 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы и содержащие их фармацевтические композиции
|
CL2008001381A1
(es)
*
|
2007-05-10 |
2008-11-03 |
Intermune Inc Y Array Biopharma Inc |
Compuestos derivados de tripeptidos que contienen heterociclos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una infeccion de hepatitis c o vih.
|
EA025794B1
(ru)
|
2007-06-29 |
2017-01-30 |
Джилид Сайэнс, Инк. |
Противовирусные соединения
|
US20090047252A1
(en)
*
|
2007-06-29 |
2009-02-19 |
Gilead Sciences, Inc. |
Antiviral compounds
|
EA200971074A1
(ru)
|
2007-06-29 |
2010-08-30 |
Джилид Сайэнс, Инк. |
Антивирусные соединения
|
EP2178885A1
(de)
|
2007-07-17 |
2010-04-28 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Makrocyclische indolderivate zur behandlung von hepatitis-c-infektionen
|
US8927569B2
(en)
|
2007-07-19 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic compounds as antiviral agents
|
US8242140B2
(en)
|
2007-08-03 |
2012-08-14 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
JP5443360B2
(ja)
|
2007-08-30 |
2014-03-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
共結晶体およびそれを含む医薬組成物
|
US8419332B2
(en)
*
|
2007-10-19 |
2013-04-16 |
Atlas Bolt & Screw Company Llc |
Non-dimpling fastener
|
WO2009076173A2
(en)
|
2007-12-05 |
2009-06-18 |
Enanta Pharmaceuticals, Inc. |
Fluorinated tripeptide hcv serine protease inhibitors
|
BRPI0821342A2
(pt)
|
2007-12-19 |
2019-09-24 |
Boehringer Ingelheim Int |
inibidores da polimerase viral
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
BRPI0908021A2
(pt)
|
2008-02-04 |
2015-07-21 |
Idenix Pharmaceuticals Inc |
Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
|
AP2010005416A0
(en)
|
2008-04-15 |
2010-10-31 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitis c virus replication.
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2720850A1
(en)
|
2008-04-28 |
2009-11-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
US8044023B2
(en)
|
2008-05-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
PT2540350E
(pt)
|
2008-07-22 |
2014-08-27 |
Merck Sharp & Dohme |
Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2350114A1
(de)
|
2008-11-20 |
2011-08-03 |
Achillion Pharmaceuticals, Inc. |
Cyclische carbonsäureamidverbindungen und analoga davon als mittel gegen das hepatitis-c-virus
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
BRPI0923184A2
(pt)
*
|
2008-12-19 |
2019-09-24 |
Gilead Sciences Inc |
inibidores de hcv ns3 protease
|
MX2011007195A
(es)
|
2009-01-07 |
2013-07-12 |
Scynexis Inc |
Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
|
EP2396028A2
(de)
|
2009-02-12 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Hcv-kombinationstherapien mit pegyliertem interferon, ribavirin und telaprevir
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
US8377962B2
(en)
|
2009-04-08 |
2013-02-19 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
JP5639155B2
(ja)
|
2009-05-13 |
2014-12-10 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
C型肝炎ウイルスインヒビターとしての大環状化合物
|
US8232246B2
(en)
*
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
EP2459582B1
(de)
|
2009-07-30 |
2015-05-27 |
Merck Sharp & Dohme Corp. |
Hvc-ns3-proteasehemmer
|
CA2769652A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
AU2010330862B2
(en)
|
2009-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
|
EP2528605A1
(de)
|
2010-01-29 |
2012-12-05 |
Vertex Pharmaceuticals Incorporated |
Therapien zur behandlung von hepatitis-c-virusinfektionen
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
EP2593105A1
(de)
|
2010-07-14 |
2013-05-22 |
Vertex Pharmaceuticals Incorporated |
Wohlschmeckende pharmazeutische zusammensetzung mit vx-950
|
RS54638B1
(en)
|
2010-09-21 |
2016-08-31 |
Enanta Pharmaceuticals, Inc. |
HCV SERIN PROTEASE INHIBITORS DERIVED FROM MACROCYCLIC PROLINE
|
US8937041B2
(en)
|
2010-12-30 |
2015-01-20 |
Abbvie, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
SG191759A1
(en)
|
2010-12-30 |
2013-08-30 |
Enanta Pharm Inc |
Phenanthridine macrocyclic hepatitis c serine protease inhibitors
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
WO2012109646A1
(en)
|
2011-02-11 |
2012-08-16 |
Vertex Pharmaceuticals Incorporated |
Treatment of hcv in hiv infection patients
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2013116339A1
(en)
|
2012-01-31 |
2013-08-08 |
Vertex Pharmaceuticals Incorporated |
High potency formulations of vx-950
|
CN102617705B
(zh)
*
|
2012-02-16 |
2014-12-31 |
上海纬诺医药科技有限公司 |
抑制丙肝病毒复制的大环类化合物
|
WO2014058794A1
(en)
|
2012-10-08 |
2014-04-17 |
Abbvie Inc. |
Compounds useful for making hcv protease inhibitors
|
JP6154474B2
(ja)
|
2012-10-19 |
2017-06-28 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
C型肝炎ウイルス阻害剤
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070964A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9334279B2
(en)
|
2012-11-02 |
2016-05-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914614B1
(de)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Inhibitoren des hepatitis-c-virus
|
US9580463B2
(en)
|
2013-03-07 |
2017-02-28 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP3046924A1
(de)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Inhibitoren des hepatitis-c-virus
|
EP3089757A1
(de)
|
2014-01-03 |
2016-11-09 |
AbbVie Inc. |
Feste antivirale darreichungsformen
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
CN110256536B
(zh)
*
|
2019-05-13 |
2022-09-13 |
中国人民解放军第二军医大学 |
一种抗丙型肝炎病毒感染合成肽及其应用
|
CN117105928B
(zh)
*
|
2023-08-22 |
2024-03-26 |
上海蓝木化工有限公司 |
一种蛋白酶抑制剂及其制备方法
|